Chemotherapy Induced Peripheral Neuropathy - Pipeline Review, H1 2018

  • ID: 4473110
  • Report
  • 128 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Achelios Therapeutics Inc
  • Asahi Kasei Corp
  • Celgene Corp
  • Kineta Inc
  • Nemus Bioscience Inc
  • PeriphaGen Inc
  • MORE
Chemotherapy Induced Peripheral Neuropathy - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Chemotherapy Induced Peripheral Neuropathy - Pipeline Review, H1 2018, provides an overview of the Chemotherapy Induced Peripheral Neuropathy (Toxicology) pipeline landscape.

Chemotherapy-induced peripheral neuropathy (CIPN) is a side effect of cancer treatment. Symptoms include pain, burning, tingling, constipation, muscle weakness, blood pressure changes and balance problems. Risk factors include longer duration of therapy, pre-existing neuropathy and type of chemotherapeutic agent.

Report Highlights:

Pharmaceutical and Healthcare latest pipeline guide Chemotherapy Induced Peripheral Neuropathy - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Chemotherapy Induced Peripheral Neuropathy (Toxicology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Chemotherapy Induced Peripheral Neuropathy (Toxicology) pipeline guide also reviews of key players involved in therapeutic development for Chemotherapy Induced Peripheral Neuropathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 5, 3, 1, 23, 2 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively.

Chemotherapy Induced Peripheral Neuropathy (Toxicology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Chemotherapy Induced Peripheral Neuropathy (Toxicology).
  • The pipeline guide reviews pipeline therapeutics for Chemotherapy Induced Peripheral Neuropathy (Toxicology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Chemotherapy Induced Peripheral Neuropathy (Toxicology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Chemotherapy Induced Peripheral Neuropathy (Toxicology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Chemotherapy Induced Peripheral Neuropathy (Toxicology)
Reasons to Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Chemotherapy Induced Peripheral Neuropathy (Toxicology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Chemotherapy Induced Peripheral Neuropathy (Toxicology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Achelios Therapeutics Inc
  • Asahi Kasei Corp
  • Celgene Corp
  • Kineta Inc
  • Nemus Bioscience Inc
  • PeriphaGen Inc
  • MORE
Introduction

Chemotherapy Induced Peripheral Neuropathy - Overview

Chemotherapy Induced Peripheral Neuropathy - Therapeutics Development

Chemotherapy Induced Peripheral Neuropathy - Therapeutics Assessment

Chemotherapy Induced Peripheral Neuropathy - Companies Involved in Therapeutics Development

Chemotherapy Induced Peripheral Neuropathy - Drug Profiles

Chemotherapy Induced Peripheral Neuropathy - Dormant Projects

Chemotherapy Induced Peripheral Neuropathy - Discontinued Products

Chemotherapy Induced Peripheral Neuropathy - Product Development Milestones

Appendix

List of Tables:

Number of Products under Development for Chemotherapy Induced Peripheral Neuropathy, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Target, H1 2018 (Contd..1), H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..1), H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Chemotherapy Induced Peripheral Neuropathy - Pipeline by Achelios Therapeutics Inc, H1 2018

Chemotherapy Induced Peripheral Neuropathy - Pipeline by Aptinyx Inc, H1 2018

Chemotherapy Induced Peripheral Neuropathy - Pipeline by Asahi Kasei Corp, H1 2018

Chemotherapy Induced Peripheral Neuropathy - Pipeline by Can-Fite BioPharma Ltd, H1 2018

Chemotherapy Induced Peripheral Neuropathy - Pipeline by Celgene Corp, H1 2018

Chemotherapy Induced Peripheral Neuropathy - Pipeline by Immune Pharmaceuticals Inc, H1 2018

Chemotherapy Induced Peripheral Neuropathy - Pipeline by Insys Therapeutics Inc, H1 2018

Chemotherapy Induced Peripheral Neuropathy - Pipeline by Kineta Inc, H1 2018

Chemotherapy Induced Peripheral Neuropathy - Pipeline by KPI Therapeutics Inc, H1 2018

Chemotherapy Induced Peripheral Neuropathy - Pipeline by Krenitsky Pharmaceuticals Inc, H1 2018

Chemotherapy Induced Peripheral Neuropathy - Pipeline by Mundipharma International Ltd, H1 2018

Chemotherapy Induced Peripheral Neuropathy - Pipeline by Nemus Bioscience Inc, H1 2018

Chemotherapy Induced Peripheral Neuropathy - Pipeline by Neurocentrx Pharma Ltd, H1 2018

Chemotherapy Induced Peripheral Neuropathy - Pipeline by Panacea Pharmaceuticals Inc, H1 2018

Chemotherapy Induced Peripheral Neuropathy - Pipeline by PeriphaGen Inc, H1 2018

Chemotherapy Induced Peripheral Neuropathy - Pipeline by PledPharma AB, H1 2018

Chemotherapy Induced Peripheral Neuropathy - Pipeline by Sova Pharmaceuticals Inc, H1 2018

Chemotherapy Induced Peripheral Neuropathy - Pipeline by Trevena Inc, H1 2018

Chemotherapy Induced Peripheral Neuropathy - Pipeline by WEX Pharmaceuticals Inc, H1 2018

Chemotherapy Induced Peripheral Neuropathy - Dormant Projects, H1 2018

Chemotherapy Induced Peripheral Neuropathy - Dormant Projects, H1 2018 (Contd..1), H1 2018

Chemotherapy Induced Peripheral Neuropathy - Discontinued Products, H1 2018

List of Figures:

Number of Products under Development for Chemotherapy Induced Peripheral Neuropathy, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Achelios Therapeutics Inc
  • Aptinyx Inc
  • Asahi Kasei Corp
  • Can-Fite BioPharma Ltd
  • Celgene Corp
  • Immune Pharmaceuticals Inc
  • Insys Therapeutics Inc
  • Kineta Inc
  • KPI Therapeutics Inc
  • Krenitsky Pharmaceuticals Inc
  • Mundipharma International Ltd
  • Nemus Bioscience Inc
  • Neurocentrx Pharma Ltd
  • Panacea Pharmaceuticals Inc
  • PeriphaGen Inc
  • PledPharma AB
  • Sova Pharmaceuticals Inc
  • Trevena Inc
  • WEX Pharmaceuticals Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll